About this trial
This clinical research aims to determine if concurrent chemotherapy and radiation therapy is more effective than sequential chemotherapy and radiation therapy for patients with stage IIB-III breast cancer. It seeks to answer the following key questions:
1. When compared to sequential treatment, does concurrent chemoradiotherapy increase disease-free survival? 2. What effects does concurrent treatment have on post-operative look, quality of life, and side effects including arm swelling (lymphoedema)? 3. What are each treatment approach's financial costs?
Researchers will compare the following to groups:
Arm A: Participants in the sequential treatment group will first undergo chemotherapy and then radiation.
and Arm B: Participants in the concurrent treatment group will undergo radiation therapy while undergoing chemotherapy.
Participants are going to:
1. Get the usual chemotherapy (taxanes and/or anthracyclines). 2. Receive radiation therapy for three to four weeks. 3. Have follow-up visits every 6months for 5years to check for cancer recurrence, side effects, and quality of life.
Eligibility criteria
Qualifiers
Pathologically confirmed invasive breast cancer
Stage IIB-III invasive breast cancer (AJCC 8th edition)
Patients planned for adjuvant chemotherapy and adjuvant radiotherapy
Patients fit to receive adjuvant chemotherapy and radiotherapy
Disqualifiers
Hypersensitivity to taxanes
Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)
Unable or unwilling for regular follow up
Bilateral tumour needed RT to both sides
Trial design
Treatments tested in this trial
- Chemoradiation
- Chemoradiation
Treatment groups
Locations
5Sponsors and collaborators
Dr. Tabassum Wadasadawala
Lead sponsor
Tata Memorial Centre
Sponsor institution